Prolonged improvement of childhood onset systemic lupus erythematosus following systematic administration of rituximab and cyclophosphamide

Pediatric Rheumatology

Volumn 12, Issue 1, 2014, Pages

  Lehman, Thomas J A ^a   Singh, Chahait ^a   Ramanathan, Anusha ^a   Alperin, Risa ^a   Adams, Alexa ^a   Barinstein, Laura ^a   Moorthy, Nandini ^b  

^a HOSPITAL FOR SPECIAL SURGERY   (United States)

^b ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTINUCLEAR ANTIBODY; CD19 ANTIGEN; COMPLEMENT COMPONENT C3; CREATININE; CYCLOPHOSPHAMIDE; HEMOGLOBIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; PREDNISONE; RITUXIMAB; SERUM ALBUMIN; ANTIRHEUMATIC AGENT; GLUCOCORTICOID; IMMUNOGLOBULIN; MONOCLONAL ANTIBODY;

ADOLESCENT; ADULT; ALBUMIN BLOOD LEVEL; ANTIBIOTIC THERAPY; ARTICLE; CHILDHOOD; CLINICAL ARTICLE; CORTICOSTEROID THERAPY; CREATININE BLOOD LEVEL; DISEASE EXACERBATION; DRUG DOSE REDUCTION; DRUG EFFICACY; ERYTHROCYTE SEDIMENTATION RATE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HOSPITALIZED CHILD; HUMAN; HYPOCOMPLEMENTEMIA; IMMUNOGLOBULIN BLOOD LEVEL; LONG TERM CARE; LUPUS ERYTHEMATOSUS NEPHRITIS; MAINTENANCE THERAPY; MALE; ONSET AGE; OUTCOME ASSESSMENT; PILOT STUDY; PRIORITY JOURNAL; PROLIFERATIVE GLOMERULONEPHRITIS; SLEDAI; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT DURATION; WELLBEING; YOUNG ADULT; BLOOD; CHEMOTHERAPY-INDUCED FEBRILE NEUTROPENIA; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG MONITORING; DRUG RESISTANCE; LUPUS ERYTHEMATOSUS, SYSTEMIC; PATIENT ACUITY; REMISSION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGE OF ONSET; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; CHEMOTHERAPY-INDUCED FEBRILE NEUTROPENIA; CYCLOPHOSPHAMIDE; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; GLUCOCORTICOIDS; HUMANS; IMMUNOGLOBULINS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; PATIENT ACUITY; PILOT PROJECTS; PREDNISONE; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 84892392981     PISSN: None     EISSN: 15460096     Source Type: Journal    
DOI: 10.1186/1546-0096-12-3     Document Type: Article

References (22)

1. Marengo MF, Waimann CA, De Achaval S, Zhang H, Garcia-Gonzalez A, Richardson MN, et al. Measuring therapeutic adherence in systemic lupus erythematosus with electronic monitoring. Lupus 2012, 21:1158-1165. 10.1177/0961203312447868, 22588588.
2. Costedoat-Chalumeau N, Amoura Z, Hulot JS, Aymard G, Leroux G, Marra D, et al. Very low blood hydroxychloroquine concentration as an objective marker of poor adherence to treatment of systemic lupus erythematosus. Ann Rheum Dis 2007, 66:821-824. 10.1136/ard.2006.067835, 1954674, 17324970.
3. Frédéric A. Houssiau. Therapy of lupus nephritis: lessons learned from clinical research and daily care of patients. Arthritis Res Ther 2012, 14:202. 10.1186/ar3656, 3392794, 22293173.
4. Bruce IN, Gladman DD, Urowitz MB. Factors associated with refractory renal disease in patients with systemic lupus erythematosus: the role of patient nonadherence. Arthritis Care Res 2000, 13:406-408. 10.1002/1529-0131(200012)13:6<406:AID-ART11>3.0.CO;2-2, 14635317.
5. Drenkard C, Dunlop-Thomas C, Easley K, Bao G, Brady T, Lim SS. Benefits of a self-management program in low-income African-American women with systemic lupus erythematosus: results of a pilot test. Lupus 2012, 21:1586-1593. 10.1177/0961203312458842, 22936126.
6. Bugni VM, Ozaki LS, Okamoto KY, Barbosa CM, Hilário MO, Len CA, Terreri MT. Factors associated with adherence to treatment in children and adolescents with chronic rheumatic diseases. J Pediatr (Rio J) 2012, 88:483-488. 10.2223/JPED.2227, 23269234.
7. Ting TV, Kudalkar D, Nelson S, Cortina S, Pendl J, Budhani S, et al. Usefulness of cellular text messaging for improving adherence among adolescents and young adults with systemic lupus erythematosus. J Rheumatol 2012, 39:174-179. 10.3899/jrheum.110771, 22089460.
8. Austin HA, Klippel JH, Balow JE, Le Riche NG, Steinberg AD, Plotz PH, et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986, 314:614-619. 10.1056/NEJM198603063141004, 3511372.
9. Carette S, Klippel JH, Decker JL, Austin HA, Plotz PH, Steinberg AD, et al. Controlled studies of oral immunosuppressive drugs in lupus nephritis. A long-term follow-up. Ann Intern Med 1983, 99:1-8. 10.7326/0003-4819-99-1-1, 6344715.
10. Lehman TJ, Onel K. Intermittent intravenous cyclophosphamide arrests progression of the renal chronicity index in childhood systemic lupus erythematosus. J Pediatr 2000, 136(2):243-247. 10.1016/S0022-3476(00)70109-0, 10657833.
11. Lehman TJ, Sherry DD, Wagner-Weiner L, McCurdy DK, Emery HM, Magilavy DB, et al. Intermittent intravenous cyclophosphamide therapy for lupus nephritis. Pediatr 1989, 114:1055-1060.
12. Harward LE, Mitchell K, Pieper C, Copland S, Criscione-Schreiber LG, Clowse ME. The impact of cyclophosphamide on menstruation and pregnancy in women with rheumatologic disease. Lupus 2013, 22:81-86. 10.1177/0961203312468624, 23263867.
13. Kallenberg CG. Could we abandon cyclophosphamide in systemic vasculitis and lupus nephritis?. Ann Rheum Dis 2013, 72(S2):ii62-ii65. Editorial.
14. Dall'Era M. Mycophenolate mofetil in the treatment of systemic lupus erythematosus. Curr Opin Rheumatol 2011, 23:454-458. Review, 10.1097/BOR.0b013e328349a1e5, 21720247.
15. Rovin BH, Furie R, Latinis K, Looney RJ, Fervenza FC, Sanchez-Guerrero J, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 2012, 64:1215-1226. 10.1002/art.34359, 22231479.
16. Furtado J, Isenberg DA. B cell elimination in systemic lupus erythematosus. Clin Immunol 2013, 146:90-103. 10.1016/j.clim.2012.11.006, 23280492.
17. Amano H, Morimoto S, Kaneko H, Tokano Y, Takasaki Y, Hashimoto H. Effect of intravenous cyclophosphamide in systemic lupus erythematosus: relation to lymphocyte subsets and activation markers. Lupus 2000, 9:26-32. 10.1177/096120330000900106, 10713644.
18. Vital EM, Dass S, Emery P. Concomitant cyclophosphamide and oral immunosuppressants with rituximab for systemic lupus erythematosus. Rheumatology (Oxford) 2012, 51:1131-1132. 10.1093/rheumatology/kes042, 22491718.
19. Turner-Stokes T, Lu TY, Ehrenstein MR, Giles I, Rahman A, Isenberg DA. The efficacy of repeated treatment with B-cell depletion therapy in systemic lupus erythematosus: an evaluation. Rheumatology (Oxford) 2011, 50:1401-1408. 10.1093/rheumatology/ker018, 21398661.
20. Mycophenolate mofetil USA approved package insert USA: Genentech (Roche), Mycophenolate mofetil.
21. Piram M, Maldini C, Mahr A. Effect of race/ethnicity on risk, presentation and course of connective tissue diseases and primary systemic vasculitides. Curr Opin Rheumatol 2012, 24:193-200. 10.1097/BOR.0b013e32835059e5, 22249352.
22. Condon MB, Griffith MH, Cook HT, Levy JB, Lighstone L, Cairns T. Treatment of Class IV lupus nephritis with rituximab and mycophenolate mofetil (MMF) with no oral steroids is effective and safe. J Am Soc Nephrol 2009, 21:419A.